We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Antipsychotic Effects of Ceruletide (Caerulein) on Chronic Schizophrenia

Takashi Moroji, MD; Noboru Watanabe, MD; Norita Aoki, MD; Shinji Itoh, MD
Arch Gen Psychiatry. 1982;39(4):485-486. doi:10.1001/archpsyc.1982.04290040079011.
Text Size: A A A
Published online


To the Editor.  —1Recently, Hökfelt et al1 postulated that an imbalance between cholecystokinin (CCK)-like peptides and dopamine in the mesolimbic dopamine system may be a cause of schizophrenia. Furthermore, they suggested that, when administered, CCK fragments may have beneficial effects on schizophrenia by reducing dopamine hyperactivity in the mesolimbic dopamine system. On the other hand, Zetler2-4 has demonstrated that CCK-8 and ceruletide (caerulein), a decapeptide chemically related to CCK-8, have neurolepticlike activity in mice. Interestingly, the central depressant effects were elicited by ceruletide in lower doses than by CCK-8. Ceruletide diethylamine is used clinically in radiologie examination of the gallbladder, biliary system, and digestive tract, and in the treatment of postoperative paralytic ileus, intestinal hypotonia, and atonia.5 We administered ceruletide to 20 chronic schizophrenic inpatients in whom neuroleptic therapy had been ineffective, to investigate the antipsychotic efficacy of CCK-like peptides.All the patients were receiving various neuroleptics during


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.